The report highlights Seikagaku Corporation's commitment to achieving sustainable development by focusing on six material issues: creation of truly useful pharmaceuticals and medical devices, provision of a stable supply of pharmaceuticals and medical devices of guaranteed quality, expansion of healthcare access and appropriate provision of high-quality medical information, fair and ethical business activities and strengthening of corporate governance, promotion of diversity and development of human resources, and engagement in environmentally friendly corporate activities. The report also outlines the company's new mid-term management plan (fiscal 2022-fiscal 2025), which aims to achieve record-high business results by accelerating R&D, maximizing the product value of SI-6603 (treatment for lumbar disc herniation), maintaining and enhancing the business value of joint function improving agents, constructing a global production system, and expanding the LAL business through recombinant technologies.
Go back to company
Seikagaku Corporation 2022 Corporate Report
Issuing Company Seikagaku Corporation
Report Type Integrated Report
Report Language EN
Report Filesize 9.12 MB
No. of Pages 32 pages
Reporting periodApril 1, 2021-March 31, 2022
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue